Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00532350 | Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease | PHASE1 | COMPLETED | 22 | — | — | Jul 1, 2007 | Jan 1, 2008 | Dec 19, 2020 | 3 | Germany |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | QAT370 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| 3 | ACTIVE_COMPARATOR | Tiotropium |
| Name | Type | Description |
|---|---|---|
| QAT370 | DRUG | - |
| Placebo | DRUG | - |
| Tiotropium | DRUG | - |
Inclusion Criteria: * Patients between 40 and 80 years of age with controlled COPD. * Women must be surgically sterilized or postmenopausal. Additional birth control and post-menopausal information will be available at time of enrollment. * Body mass index (BMI) must be within the range of 18 to 32...